Placebo Effect of Paracetamol in Healthy Volunteers (HOP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01053650|
Recruitment Status : Completed
First Posted : January 21, 2010
Last Update Posted : January 30, 2012
Paracetamol is one of the most commonly used drugs in the world, indicated for the symptomatic treatment of fever and pain of mild to moderate. More precisely, it is a drug used to relieve pain and reduce fever. The objective of this study is to analyze whether a placebo effect occurs when you take paracetamol for pain, ie if the analgesic effect of paracetamol is partly due to the simple fact of taking a drug.
Moreover, during the study you propose to do a saliva sample, optional, for biological research, pharmacogenetics, to assess how paracetamol is processed and eliminated in your body..
|Condition or disease||Intervention/treatment||Phase|
|Healthy Volunteers||Drug: Paracetamol||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Care Provider)|
|Official Title:||Placebo Effect of Paracetamol in Healthy Volunteers|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||February 2010|
|Actual Study Completion Date :||February 2010|
- Drug: Paracetamol
Clinical trial conducted in healthy volunteers, prospective, single center, randomized, open / hidden.
- The main objective of this protocol is to assess the placebo effect in healthy volunteers by comparing pain thresholds and tolerance between two passages, when taking paracetamol.
- The secondary objectives of this study are 1 - explore, through testing Cantab ®, if the administration of paracetamol alter performance on cognitive tests. 2 - to analyze the determination of paracetamol and its metabolites in urine and blood samples,
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01053650
|Clermont-Ferrand, France, 63003|
|Principal Investigator:||Gisèle Pickering, MCU-PH||University Hospital, Clermont-Ferrand|